Jubilant Pharmova Q2 and H1 FY26 results approved with clean review

Related Party TransactionsResults View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹1118.20

prior close

₹1127.70

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.6%-2.0% vs market

Pharmaceuticals peers, median of 153sector-0.4%-2.1% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Smallcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.1

10m

-1.6

15m

-1.6

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.6-2.0-0.4-2.1

Next day

+3.6+0.1+3.5+0.1+3.5

+5.3-0.5+5.8-0.4+5.6

+4.6-2.0+6.6-1.5+6.2

+0.4-2.2+2.6-1.6+2.0

+1.9-2.3+4.2-2.5+4.4

+2.0-1.7+3.7-2.0+4.0

15d

-3.8-4.6+0.8-4.0+0.2

-1.1-3.7+2.5-3.9+2.7

-4.2-4.2-0.0-5.4+1.2

-14.2-10.9-3.3-11.1-3.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved standalone and consolidated unaudited results for the quarter and half year ended September 30, 2025. Walker Chandiok and Co LLP found no material misstatement and did not modify its conclusion. The consolidated review notes an associate's unreviewed net loss of ₹1 million for Q2 and ₹2 million for H1, considered immaterial. Related-party dealings were also disclosed.

Likely market impact

The clean review supports credibility, but shareholders need the full results to assess earnings momentum and stock impact.